eMedicine Specialties > Emergency Medicine > Trauma & Orthopedics

Nailbed Injuries: Treatment & Medication

Author: Darrell Sutijono, MD, Staff Physician, Department of Emergency Medicine, State University of New York, Downstate; Kings County Hospital
Coauthor(s): Mark A Silverberg, MD, FACEP, MMB, Assistant Professor, Assistant Residency Director, Department of Emergency Medicine, State University of New York Downstate College of Medicine; Consulting Staff, Department of Emergency Medicine, Staten Island University Hospital, Kings County Hospital, University Hospital, State University of New York Downstate at Brooklyn
Contributor Information and Disclosures

Updated: Jul 16, 2009

Treatment

Emergency Department Care

  • Subungual hematoma
    • Small and painless subungual hematomas require no treatment, as blood will be incorporated into the surrounding tissues and eventually be removed with the free edge. If the subungual hematoma covers more than 25% of the nailbed or is causing pain it should be evacuated via trephination (see Hand, Subungual Hematoma Drainage).
    • The treatment of subungual hematomas covering greater than 25-50% of the nailbed is controversial. The standard of care has been to remove the nail and repair any underlying laceration because 50% of hematomas have significant nail bed lacerations. The incidence increases to 94% when associated with distal phalangeal fracture, regardless of the size of the hematoma.
    • Recent studies have concluded that as long as the nail is still partially adherent to the nailbed or paronychia and is not displaced out of the nail fold, removal of the nail and repair of the nailbed does not improve outcome versus simple trephination. No correlation was found between adverse outcome and the size of the hematoma or presence of an associated fracture.4,3,5
    • The advantages of simple trephination alone are less pain for the patient, shorter length of stay, and less costly intervention.3
  • Evacuation of hematomas


Trephination of a subungual hematoma.

Trephination of a subungual hematoma.

Trephination of a subungual hematoma.

Trephination of a subungual hematoma.

    • Various methods of trephination exist. The easiest and safest is to use an electric cautery, which melts a hole through the nail. Once the cautery encounters the underlying hematoma, the tip cools, preventing further injury to the nailbed. If the hole is of adequate size, blood will drain and relieve some pain and the pressure sensation for the patient.
    • A paper clip may also be used after it is heated until red hot.
    • Use of an 18-gauge needle is less optimal because of the risk of injury to the nailbed once the nail has been penetrated.
    • An alternative technique is use of a sterile 29-gauge extra-fine insulin syringe needle.6 Instead of penetrating the nail, the needle is inserted at the hyponychium parallel to the nail, aimed at the most distal portion of the hematoma. Care is taken to keep the needle closer to the nail versus the nail bed. Once the hematoma is penetrated the needle may be withdrawn, and light pressure placed on the nail will help with evacuation of the hematoma. This technique may obviate the need for digital block anesthesia, and also may be favorable in evacuating hematomas of the smaller toe nailbeds, where trephination is more difficult.
  • Nailbed repair: Principles of treatment include minimal debridement, preservation of as much tissue as possible, atraumatic wound care, and splinting with the nail or an alternative material.


Nailbed repair.

Nailbed repair.

Nailbed repair.

Nailbed repair.

    • A digital block of 1% lidocaine hydrochloride without epinephrine provides anesthesia of sufficient duration for most repairs. Bupivacaine extends anesthesia time 4-8 hours for longer procedures. A metacarpal or an axillary block may be used for multiple nailbed injuries.
    • Children may require conscious sedation.
    • The hand should be prepared with povidone-iodine (Betadine) and covered with sterile drapes. The injured finger should be exsanguinated with a half-inch or 1-inch Penrose drain wrapped in a distal to proximal direction and placed around the base to serve as a tourniquet and provide a blood-free field.
    • The nail is elevated using the blades of either fine or curved iris scissors or small elevator scissors. Specific care is necessary to not injure the nailbed. A blunt dissecting technique should be used, and the scissors are placed gently underneath the nail until they reach the nail fold. Slowly open the scissors as it is removed. Care must again be taken to avoid further damage to the underlying nailbed or overlying nail fold. Once the nail is sufficiently separated from the nailbed, it is gently removed by applying firm and steady distal traction using a hemostat.
    • Lacerations to the nailbed should be repaired using 6-0 or smaller absorbable sutures. Minimal to no debridement should be performed because aggressive debridement may cause undue tension on the repair and results in scarring.
    • When repairing avulsed nails and nailbeds, if the nail is detached proximally, it must be removed to inspect for any damage to the nailbed. Careful inspection of the nail is important because often only a fragment of nailbed may be attached to the undersurface of the avulsed nail. Only outer and dorsal surfaces of the nail should be cleaned. Any large fragments of nailbed should be preserved for use as a free graft. Crushing injuries leave many small pieces of nailbed. If all fragments are not incorporated into the repair, they may grow independently and cause nail horns or spicules. If tissue is not available and the defect is small enough, the area will heal effectively by secondary intention.
    • Simple dorsal roof lacerations can often be repaired by accurately repairing the skin overlying the nail fold. However, if possible, suturing of the dorsal roof with a 7-0 chromic suture may provide more accurate repair. Associated paronychial injuries must be repaired and stented to prevent pterygium or adhesions, as it serves as a mold to coax nail to grow along a proper path. Distal phalangeal fracture reduction and healing is important to final nail formation. Poor reduction of the bone translates directly into irregularities of the nailbed.
    • A small hole should be made in the nail, preferably so that it is not overlying the laceration, to allow drainage and thus prevent a growing hematoma to separate the nail from the nailbed.
    • The nail is then placed back in the nail fold as a stent and held in position by 5-0 or smaller nylon sutures placed as follows:
      • Distally through the hyponychium and the nail
      • Through a half-buried horizontal mattress suture placed down proximal to the nail fold into proximal nail then back out the nail fold
      • Through the paronychia and nail bilaterally
      • As a dorsal figure-of-eight suture7 - A suture is placed transversely just distal to the hyponychium then placed proximal to the nail fold in the same direction and tied back to itself. If the nail slips laterally, 2 small vertical cuts may be made in the nail for the suture to catch upon.
    • The use of tissue adhesives such as Indermil (n- butyl cyanoacrylate) or Dermabond (octyl-2-cyanoacrylate) is a less invasive option for nailbed and nail repair.8,9,10,11
      • Nail fragments may be repaired together first using adhesive, then secured into the nail fold by a thin layer placed under the nail, using gentle downward pressure while the adhesive dries.
      • Alternatively, nail fragments may be pieced together on the nailbed, with a light coating of adhesive wiped or dripped between adjoining fragments and on skin adjacent to the perimeter of the nail. As the adhesive dries, use forceps to maintain external pressure.
      • Chloramphenicol ointment may be used in a similar fashion for simple lacerations, with a small amount applied under the nail so that the ointment forms an adhesive layer as it is positioned into the nail fold.12
    • The proximal nail should be reinserted into the nail fold. The replaced nail keeps the nail fold open for new nail growth and provides a protective cover for the nailbed and a precise template for new nail to follow as it regenerates. It also serves as a rigid splint for any underlying fractures and reduces postoperative discomfort and improves postoperative function.
    • If the original nail is missing, nonadherent gauze, aluminum suture package material, 0.020-inch reinforced silicone sheeting, acrylic (artificial) nail13 , or splints made from hypodermic syringes14 or nasogastric tubing15 may be used as the splint in place of the nail.
    • Dress the injured finger with nonadherent gauze and 2-inch gauze roll then splint the finger.

Consultations

A hand surgeon should be consulted for significantly avulsed nail matrix or for severe crush injuries.

Medication

The goal of pharmacotherapy is to reduce pain and to prevent infection. If not updated, tetanus immunization is indicated.

Antibiotics

Therapy must cover all likely pathogens in the context of the clinical setting. The prophylactic use of antibiotics is indicated depending on mechanism and extent of injury, such as for crush injuries and human or animal bites. Although the benefit of prophylactic antibiotics has not been proven, even if an open fracture of the distal phalanx is present, to be safe, many clinicians still prescribe a first-generation cephalosporin when bone or joint are exposed below a nailbed injury. A large, randomized controlled study may be necessary in the near future to examine the utility of antibiotics in such circumstances.


Cephalexin (Keflex, Biocef)

First-generation cephalosporin that inhibits bacterial growth by inhibiting bacterial cell wall synthesis. Bactericidal and effective against rapidly growing organisms forming cell walls. Acceptable alternative to penicillin and may be useful in patients with minor penicillin allergies.

Adult

250-500 mg PO qid

Pediatric

25-50 mg/kg/d PO divided q6h

Aminoglycosides increase nephrotoxic potential of cephalexin

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Adjust dose in renal impairment

Nonsteroidal anti-inflammatory agents (NSAIDs)

NSAIDs are commonly used for relief of mild to moderate pain. Effects of NSAIDs in treating pain tend to be patient specific, but ibuprofen is usually the DOC for initial therapy. Other options include ketoprofen, flurbiprofen, and naproxen.


Ibuprofen (Ibuprin, Advil, Motrin)

Usually DOC for treatment of mild to moderate pain if no contraindications exist. Decreases inflammatory reactions and pain by inhibiting the activity of the enzyme cyclooxygenase, resulting in diminished prostaglandin synthesis.

Adult

400-800 mg PO q4-6h; not to exceed 3200 mg/d

Pediatric

<12 years: 10 mg/kg/dose PO qid
>12 years: Administer as in adults

Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; monitor PT closely (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently

Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency; high risk of bleeding; because of potential cross-sensitivity to other NSAIDs, do not administer to patients hypersensitive to aspirin, iodides, or other NSAIDs

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Caution in congestive heart failure, hypertension, and decreased renal and hepatic function; caution in anticoagulation abnormalities or during anticoagulant therapy


Flurbiprofen (Ansaid)

Has analgesic, antipyretic, and anti-inflammatory effects. Decreases inflammatory reactions and pain by inhibiting the activity of the enzyme cyclooxygenase, resulting in diminished prostaglandin synthesis.

Adult

200-300 mg/d PO divided bid/qid

Pediatric

Not established

Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; monitor PT closely (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Acute renal insufficiency, interstitial nephritis, hyperkalemia, hyponatremia, and renal papillary necrosis may occur; patients with preexisting renal disease or compromised renal perfusion risk acute renal failure; leukopenia occurs rarely, is transient, and usually returns to normal during therapy; persistent leukopenia, granulocytopenia, or thrombocytopenia warrants further evaluation and may require discontinuation of drug


Ketoprofen (Oruvail, Orudis, Actron)

Used for relief of mild to moderate pain and inflammation. For patients with a small body size, elderly persons, and those with renal or liver disease, initially administer small dosages. Doses >75 mg do not increase therapeutic effects. Administer high doses with caution and closely observe patients' responses.

Adult

25-50 mg PO q6-8h prn; not to exceed 300 mg/d

Pediatric

<3 months: Not established
3 months to 14 years: 0.1-1 mg/kg PO q6-8h
>12 years: Administer as in adults

Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; monitor PT closely (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Caution in congestive heart failure, hypertension, and decreased renal and hepatic function; caution in anticoagulation abnormalities or during anticoagulant therapy


Naproxen (Anaprox, Naprelan, Naprosyn)

Used for relief of mild to moderate pain. Decreases inflammatory reactions and pain by inhibiting the activity of the enzyme cyclooxygenase, resulting in diminished prostaglandin synthesis.

Adult

500 mg PO followed by 250 mg q6-8h; not to exceed 1.25 g/d

Pediatric

<2 years: Not established
>2 years: 2.5 mg/kg/dose PO; not to exceed 10 mg/kg/d

Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; monitor PT closely (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently

Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency; high risk of bleeding

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Acute renal insufficiency, interstitial nephritis, hyperkalemia, hyponatremia, and renal papillary necrosis may occur; patients with preexisting renal disease or compromised renal perfusion risk acute renal failure; leukopenia occurs rarely, is transient, and usually returns to normal during therapy; persistent leukopenia, granulocytopenia, or thrombocytopenia warrants further evaluation and may require discontinuation of drug

Analgesics

These agents are commonly used for relief of mild to severe pain.


Acetaminophen (Tylenol, Panadol, Aspirin-free Anacin)

DOC for pain in patients with documented hypersensitivity to aspirin or NSAIDs, with upper GI disease, or who are taking oral anticoagulants.

Adult

325-650 mg PO q4-6h or 1000 mg PO tid/qid; not to exceed 4 g/d PO

Pediatric

<12 years: 10-15 mg/kg/dose PO q4-6h prn; not to exceed 2.6 g/d
>12 years: 325-650 mg PO q4h; not to exceed 5 doses/d

Rifampin can reduce analgesic effects of acetaminophen; coadministration with barbiturates, carbamazepine, hydantoins, and isoniazid may increase hepatotoxicity

Documented hypersensitivity; known G-6-P deficiency

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Severe or recurrent pain or high or continued fever may indicate a serious illness; acetaminophen is contained in many OTC products and combined use with these products may result in cumulative acetaminophen doses exceeding recommended maximum dose


Acetaminophen and codeine (Tylenol #3)

Drug combination indicated for treatment of mild to moderate pain.

Adult

30-60 mg/dose PO based on codeine content q4-6h or 1-2 tab q4h; not to exceed 12 tab/d

Pediatric

0.5-1 mg/kg/dose PO based on codeine q4-6h; 10-15 mg/kg/dose PO based on acetaminophen content; not to exceed 2.6 g/d of acetaminophen

Toxicity increases with CNS depressants or tricyclic antidepressants

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Caution in patients dependent on opiates since this substitution may result in acute opiate-withdrawal symptoms; caution in severe renal or hepatic dysfunction


Hydrocodone bitartrate and acetaminophen (Vicodin ES)

Drug combination indicated for the relief of moderate to severe pain.

Adult

1-2 tab or cap PO q4-6h prn; not to exceed 4 g/d of acetaminophen

Pediatric

<12 years: 10-15 mg/kg/dose acetaminophen PO q4-6h prn; not to exceed 2.6 g/d acetaminophen
>12 years: 750 mg acetaminophen PO q4h; not to exceed 10 mg hydrocodone bitartrate per dose or 5 doses/24 h

Coadministration with phenothiazines may decrease analgesic effects; toxicity increases with CNS depressants or tricyclic antidepressants

Documented hypersensitivity; high altitude cerebral edema (HACE) or elevated intracranial pressure (ICP)

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Tab contain metabisulfite, which may cause hypersensitivity; caution in patients dependent on opiates since this substitution may result in acute opiate-withdrawal symptoms; caution in severe renal or hepatic dysfunction


Oxycodone and acetaminophen (Percocet)

Drug combination indicated for the relief of moderate to severe pain. DOC for aspirin-hypersensitive patients.

Adult

1-2 tab or cap PO q4-6h prn; not to exceed 4 g/d of acetaminophen

Pediatric

0.05-0.15 mg/kg/dose PO oxycodone; not to exceed 5 mg/dose of oxycodone q4-6h prn

Phenothiazines may decrease analgesic effects of this medication; toxicity increases with coadministration of either CNS depressants or tricyclic antidepressants

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Duration of action may increase in elderly patients; be aware of total daily dose of acetaminophen that patient is receiving

Toxoid

This agent is used for tetanus immunization. Administer booster injection in previously immunized individuals to prevent this potentially lethal syndrome.


Tetanus toxoid

Used to induce active immunity against tetanus in selected patients. The immunizing agent of choice for most adults and children aged > 7 y are tetanus and diphtheria toxoids. Necessary to administer booster doses to maintain tetanus immunity throughout life. Pregnant patients should receive only tetanus toxoid, not a diphtheria antigen-containing product. May administer into deltoid or midlateral thigh muscles in children and adults. In infants, preferred site of administration is the mid thigh laterally.

Adult

Primary immunization: 0.5 mL IM, give 2 injections 4-8 wk apart and a third dose 6-12 mo after second injection
Booster dose: 0.5 mL q10y

Pediatric

Administer as in adults

Patients receiving immunosuppressants, including corticosteroids or radiation therapy, may remain susceptible despite immunization due to poor immune response; cimetidine may enhance or augment delayed-hypersensitivity responses to skin-test antigens; avoid concurrent use of medication with systemic chloramphenicol because it may impair amnestic response to tetanus toxoid; concurrent use of tetanus immune globulin may delay development of active immunity by several days (interaction is, nevertheless, clinically insignificant and does not preclude its concurrent use)

Documented hypersensitivity; a history of any type of neurologic symptoms or signs following administration of this product; FDA recommends that elective tetanus immunization be deferred during any outbreak of poliomyelitis because tetanus toxoid injections are an important cause of provocative poliomyelitis

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Do not use to treat actual tetanus infections, or for immediate prophylaxis of unimmunized individuals (instead use tetanus antitoxin, preferably human tetanus immune globulin); diminished antibody response to active immunization may be observed in patients receiving immunosuppressive therapy; better to defer primary diphtheria immunization until immunosuppressive therapy discontinued; routine immunization of symptomatic and asymptomatic HIV-infected persons is recommended

Immunoglobulins

Patients who may not have been immunized against Clostridium tetani products should receive tetanus immune globulin (Hyper-Tet).


Tetanus immune globulins (Hyper-Tet)

Used for passive immunization of persons with wounds that may be contaminated with tetanus spores.

Adult

Prophylaxis: 250-500 U IM in extremity opposite to tetanus toxoid injection site
Clinical tetanus: 3000-10,000 U IM

Pediatric

Administer as in adults

Since antibodies in globulin preparation may interfere with immune response to vaccination, do not administer within 3 mo of live-virus immune globulin administration; may be necessary to revaccinate persons who received immune globulin shortly after live-virus vaccination

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Persons with isolated IgA deficiency have potential for developing antibodies to IgA and could have anaphylactic reactions to subsequent administration of blood products that contain IgA; do not perform skin testing because intradermal injection of concentrated gamma globulin may cause localized area of inflammation and can be misinterpreted, causing the medication to be withheld from a patient not allergic to this material; true allergic responses to human gamma globulin given in prescribed IM manner are extremely rare; do not admix with other medications because they are usually incompatible

More on Nailbed Injuries

Overview: Nailbed Injuries
Differential Diagnoses & Workup: Nailbed Injuries
Treatment & Medication: Nailbed Injuries
Follow-up: Nailbed Injuries
Multimedia: Nailbed Injuries
References

References

  1. Inglefield CJ, D'Arcangelo M, Kolhe PS. Injuries to the nail bed in childhood. J Hand Surg [Br]. Apr 1995;20(2):258-61. [Medline].

  2. de Alwis W. Fingertip Injuries. Emerg Med Australas. Jun 2006;18(3):229-37. [Medline].

  3. Roser SE, Gellman H. Comparison of nail bed repair versus nail trephination for subungual hematomas in children. J Hand Surg [Am]. Nov 1999;24(6):1166-70. [Medline].

  4. Meek S, White M. Subungual haematomas: is simple trephining enough?. J Accid Emerg Med. Jul 1998;15(4):269-71. [Medline].

  5. Seaberg DC, Angelos WJ, Paris PM. Treatment of subungual hematomas with nail trephination: a prospective study. Am J Emerg Med. May 1991;9(3):209-10. [Medline].

  6. Kaya TI, Tursen U, Baz K, Ikizoglu G. Extra-Fine Insulin Syringe Needle: An Excellent Instrument for the Evacuation of Subungual Hematoma. Dermatol Surg. Nov 2003;29(11):1141-3. [Medline].

  7. Jeys LM, Khafagy R. A useful technique for securing nails: the figure-of-eight suture. Br J Plast Surg. Oct 2001;54(7):651. [Medline].

  8. Richards AM, Crick A, Cole RP. A novel method of securing the nail following nail bed repair. Plast Reconstr Surg. Jun 1999;103(7):1983-5. [Medline].

  9. Hallock GG, Lutz DA. Octyl-2-Cyanoacrylate adhesive for rapid nail plate restoration. J Hand Surg [Am]. Sep 2000;25(5):979-81. [Medline].

  10. Hallock GG. Expanded applications for octyl-2-cyanoacrylate as a tissue adhesive. Ann Plast Surg. Feb 2001;46(2):185-9. [Medline].

  11. Strauss EJ, Weil WM, Jordan C, Paksima N. A Prospective, Randomized Controlled Trial of 2-Octylcyanoacrylate Versus Suture Repair for Nail Bed Injuries. J Hand Surg [Am]. Feb 2008;33(2):250-3. [Medline].

  12. Pasapula C, Strick M. The use of chloramphenicol ointment as an adhesive for replacement of the nailplate after simple nail bed repairs. J Hand Surg [Br]. Dec 2004;29(6):634-5. [Medline].

  13. Purcell EM, Hussain M, McCann J. Fashionable splint for nailbed lacerations: the acrylic nail. Plast Reconstr Surg. Jul 2003;112(1):337-8. [Medline].

  14. Etoz A, Kahraman A, Ozgenel Y. Nail bed secured with a syringe splint. Plast Reconstr Surg. Nov 2004;114(6):1682-3. [Medline].

  15. Bayraktar A, Ozcan M. A nasogastric catheter splint for a nailbed. Ann Plast Surg. Jul 2006;57(1):120. [Medline].

  16. Abbase EH, Tadjalli HE, Shenaq SM. Fingertip and nail bed injuries. Repair techniques for optimum outcome. Postgrad Med. Nov 1995;98(5):217-9, 223-4, 230 passim. [Medline].

  17. Brown RE. Acute nail bed injuries. Hand Clin. Nov 2002;18(4):561-75. [Medline].

  18. Chudnofsky CR, Sebastian S. Special wounds. Nail bed, plantar puncture, and cartilage. Emerg Med Clin North Am. Nov 1992;10(4):801-22. [Medline].

  19. Guy RJ. The etiologies and mechanisms of nail bed injuries. Hand Clin. Feb 1990;6(1):9-19; discussion 21. [Medline].

  20. Harrison BP, Hilliard MW. Emergency department evaluation and treatment of hand injuries. Emerg Med Clin North Am. Nov 1999;17(4):793-822. [Medline].

  21. Hart RG, Kleinert HE. Fingertip and nail bed injuries. Emerg Med Clin North Am. Aug 1993;11(3):755-65. [Medline].

  22. Melone CP Jr, Grad JB. Primary care of fingernail injuries. Emerg Med Clin North Am. May 1985;3(2):255-61. [Medline].

  23. Shepard GH. Management of acute nail bed avulsions. Hand Clin. Feb 1990;6(1):39-56; discussion 57-8. [Medline].

  24. Stevenson TR. Fingertip and nailbed injuries. Orthop Clin North Am. Jan 1992;23(1):149-59. [Medline].

  25. Van Beek AL, Kassan MA, Adson MH, Dale V. Management of acute fingernail injuries. Hand Clin. Feb 1990;6(1):23-35; discussion 37-8. [Medline].

  26. Zook EG. Anatomy and physiology of the perionychium. Hand Clin. Feb 1990;6(1):1-7. [Medline].

  27. Zook EG. Understanding the perionychium. J Hand Ther. Oct-Dec 2000;13(4):269-75. [Medline].

Further Reading

Keywords

nailbed injury, nailbed injuries, finger injury, nail bed injuries, fingertip injuries, finger tip injuries, nail anatomy, nail loss, abnormal growth of nail, nonadherence of new nail, splitting of the nail, soft tissue infection of the nail, osteomyelitis of the underlying distal tuft

Contributor Information and Disclosures

Author

Darrell Sutijono, MD, Staff Physician, Department of Emergency Medicine, State University of New York, Downstate; Kings County Hospital
Darrell Sutijono, MD is a member of the following medical societies: American Academy of Emergency Medicine and American College of Emergency Physicians
Disclosure: Nothing to disclose.

Coauthor(s)

Mark A Silverberg, MD, FACEP, MMB, Assistant Professor, Assistant Residency Director, Department of Emergency Medicine, State University of New York Downstate College of Medicine; Consulting Staff, Department of Emergency Medicine, Staten Island University Hospital, Kings County Hospital, University Hospital, State University of New York Downstate at Brooklyn
Mark A Silverberg, MD, FACEP, MMB is a member of the following medical societies: American College of Emergency Physicians, American Medical Association, Council of Emergency Medicine Residency Directors, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Medical Editor

Eric M Kardon, MD, FACEP, Attending Emergency Physician, Georgia Emergency Medicine Specialists; Physician, Division of Emergency Medicine, Athens Regional Medical Center
Eric M Kardon, MD, FACEP is a member of the following medical societies: American College of Emergency Physicians
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Tom Scaletta, MD, President, Emergency Excellence (EmEx) (www.emergencyexcellence.com); Assistant Professor of Emergency Medicine, Rush Medical College, Cook County Hospital; Chairperson, Department of Emergency Medicine, Edward Hospital; Past-President, American Academy of Emergency Medicine
Tom Scaletta, MD is a member of the following medical societies: American Academy of Emergency Medicine and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

CME Editor

John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center
John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Chief Editor

Rick Kulkarni, MD, Medical Director, Assistant Professor of Surgery, Section of Emergency Medicine, Yale-New Haven Hospital
Rick Kulkarni, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: WebMD Salary Employment

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.